
The ‘Great Blue Hole' Mystery — How Jacques Cousteau's 1971 Expedition Took It Mainstream
In the heart of the Caribbean, off the coast of Belize, lies a near-perfect underwater sinkhole. In ... More 1971, Jacques Cousteau's expedition mapped its depths, uncovering clues to its ancient origins.
Sinkholes are natural depressions that form when rock dissolves or collapses, creating deep voids in the ground. While they are commonly found on land, they also exist in the ocean, often appearing as deep, circular pits in shallow coastal waters. These oceanic sinkholes typically originate from limestone caves that formed thousands of years ago, when sea levels were much lower. Over time, as rising waters flooded these caves, some collapsed, leaving behind the massive, submerged sinkholes we see today.
One of the largest and most famous of these is the Great Blue Hole, located off the coast of Belize. Measuring over 1,043 feet across and about 407 feet deep, this massive submarine sinkhole was known to local fishermen for generations. However, it wasn't until the mid-20th century, as ocean exploration advanced, that it gained international attention.
As interest in the world's oceans grew, so did the curiosity surrounding this geological anomaly.
By the late 1960s, ocean exploration was undergoing a transformation. Advancements in scuba technology, underwater photography and submersibles were making the deep sea more accessible than ever, while a surge in public fascination — driven by television and scientific curiosity — was pushing marine research into the mainstream.
At the forefront of this movement was Jacques Cousteau, a former French naval officer turned oceanographer, filmmaker and conservationist. Having already brought global attention to remote reefs, ancient shipwrecks and ecologically vital marine habitats, Cousteau had become a household name, blending scientific discovery with visual storytelling in ways no one had done before.
In 1971, Jacques Cousteau and his crew aboard the research vessel Calypso arrived in Belize to explore the Great Blue Hole — a massive, perfectly circular submarine sinkhole located in the Lighthouse Reef Atoll. This expedition was part of their renowned television series, The Undersea World of Jacques Cousteau.
Though geologists already understood its karstic origins to some degree, Cousteau's approach to exploration was different. He was there to show it to the world. He was so enthralled, in fact, that he subsequently ranked it among his top ten scuba diving sites in the world.
Cousteau's expedition provided the first widely publicized visual evidence that the Great Blue Hole had once been a dry limestone cave — formed during the last Ice Age, when sea levels were lower. His team's footage of submerged stalactites supported existing geological theories, showing that the cave had collapsed and flooded as the oceans rose.
In the years that followed, the Great Blue Hole became a popular dive site, attracting marine researchers, geologists and adventurers eager to explore its mysteries. While its striking vertical walls and massive submerged stalactites remained a major draw, divers also began documenting the varied marine life that inhabits the sinkhole, including Caribbean reef sharks, giant groupers and other deep-sea species that navigate its depths.
However, a true, detailed mapping of the Great Blue Hole wouldn't happen until nearly five decades later, when advancements in sonar technology and submersibles allowed for a complete digital reconstruction of the sinkhole's interior.
It wasn't until 2018 that Aquatica Submarines, in collaboration with Fabien Cousteau, Richard Branson and sub pilot Erika Bergman, used advanced sonar technology to create the first complete 3D digital model of its interior.
The exploration encountered a thick hydrogen sulfide layer at 300 feet, blocking out oxygen and light, creating a dead zone where no marine life could survive. Below this, the water was completely anoxic, preserving everything that had fallen in — including plastic waste and dead conches, which had sunk to the bottom without decomposing due to the extreme conditions.
The mapping also revealed a calcium carbonate layer at 290 feet, evidence that a thriving coral reef had once existed here before being submerged by rising seas. Additionally, divers observed sandfalls cascading down the sinkhole's walls, a process that suggests the Great Blue Hole is slowly filling in over time.
The expedition was broadcast live on Discovery Channel. But while the technology had changed, the mission remained the same: to explore, document and inspire a new generation to understand and protect the ocean's wonders.
While the 2018 expedition gave us the first complete map of the Great Blue Hole, scientists have since discovered that its greatest secret is what's buried at the bottom.
A November 2020 study extracted a nearly 9-meter-long core of sediment from the Great Blue Hole's floor, revealing a 1,885-year-long record of climate change in the Caribbean. Each layer of sediment acts like a page in a history book, showing how sea temperatures, storm activity and even human influence have changed over time.
The findings confirmed that sea temperatures have been rising for nearly 2,000 years, with long-term climate patterns like 'El Niño' and the 'Atlantic Multidecadal Oscillation' playing a major role. The sediment also shows that hurricane activity peaked between 900 and 1300 CE — during what's known as the Medieval Warm Period — when storms became more intense and frequent, eroding coastlines and washing more material into the Blue Hole.
But the most surprising discovery was evidence of modern human impact. The study found a sudden change in carbon composition after 1900, linked to the Industrial Revolution and the rise of fossil fuel emissions — a phenomenon known as the Suess Effect. This means that even this remote underwater sinkhole, first explored for its natural beauty, is now a record of human-caused climate change.
Want to see where your own climate concerns fit in to this larger trend? Take the science-backed Climate Change Worry Scale now and find out how your perspective compares.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Sanofi to acquire Blueprint for up to $9.5B
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Looking to further amp up its immunology business, Sanofi has agreed to acquire Blueprint Medicines in a deal that could be worth as much as $9.5 billion. Blueprint's research revolves around an enzyme made by a gene called KIT. This 'tyrosine kinase' enzyme helps control cell development, division and survival, so if it mutates, it can spur the type of uncontrolled cell growth seen in cancer and some rare diseases. Blueprint already has one medicine approved by the Food and Drug Administration, Ayvakit, and is working on a handful of others, two of which are in human testing. The FDA first approved Ayvakit in early 2020 for a rare kind of hard-to-treat gastrointestinal tumor, and specifically for the small subset of adults who have these tumors and certain mutations. Since then, the agency cleared the medicine as a treatment for both the less and more aggressive forms of 'systemic mastocytosis,' an uncommon disorder where a kind of white blood cell known as a mast cell builds up in the bone marrow, digestive tract, skin and other organs. The accumulation can lead to severe inflammation and organ damage. Last year, Blueprint posted $479 million in net product revenue from Ayvakit. The company used to have another marketed cancer drug, Gavreto, which it was co-developing and commercializing with Roche. But Roche ultimately backed away from that alliance, leading Blueprint to sell away rights to Rigel Pharmaceuticals in early 2024. In a statement announcing the deal, Sanofi highlighted the recent trajectory in Ayvakit sales. They were up more than 60%, for example, between the first quarter of 2024 and the same three-month period this year. Blueprint recorded a $67 million net loss in 2024, compared to a more than half-a-billion-dollar net loss in each of the previous two years. The proposed acquisition 'represents a strategic step forward in our rare and immunology portfolios,' Sanofi CEO Paul Hudson said in the Monday statement. 'It enhances our pipeline and accelerates our transformation into the world's leading immunology company.' Hudson added that his company maintains a 'sizeable capacity for further acquisitions.' After being an active dealmaker over the past few years, the French pharmaceutical giant still had close to 8 billion euros in cash and cash equivalents at the end of March. Sanofi bought the diabetes drug developer Provention Bio for almost $3 billion in 2023 and the rare disease-focused Inhibrix for $2.2 billion in 2024. And just last month, it agreed to spend $470 million on Vigil Neuroscience, a Massachusetts-based biotechnology company touting an Alzheimer's disease drug that just finished an early-stage human study. Similar to its Vigil proposal, Sanofi is offering Blueprint investors a so-called contingent value right that could be worth up to $6 per Blueprint share, provided one of the biotech's experimental drugs, 'BLU-808,' hits certain development and regulatory goals. BLU-808 is in mid-stage testing as a possible treatment for chronic hives and an allergy-related condition that causes runny eyes and a congested nose. Blueprint also believes the drug could be useful in treating allergic asthma and 'mast cell activation syndrome.' Another Blueprint drug, elenestinib, is further along, having advanced to a late-stage study for the slower-moving form of systemic mastocytosis. Sanofi's upfront payment of $9.1 billion values Blueprint shares at $129 apiece, reflecting a premium of about 27% from the biotech's closing stock price on Friday. The transaction is expected to close sometime between July and the end of September, according to Sanofi. Andrew Berens, an analyst at the investment firm Leerink Partners, wrote in a note to clients how his team expected Blueprint to land on the 'strategic radar of large pharma' given Ayvakit is on the path to $1 billion or more in annual sales and the company recently raised its financial guidance for this year. However, the deal came sooner than anticipated, ahead of a key data readout for a rival drug from Cogent Biosciences. Cogent's bezuclastinib is also being evaluated as a treatment for systemic mastocytosis, with results set to arrive in the next couple months. Regardless of how strong or weak those results will be, Berens believes they'd serve as a tailwind for Blueprint 'by removing a key overhang and allowing a strategic acquirer to structure a deal based on assumptions about ... market dynamics.' As such, Cogent's data could have propped up Blueprint's share price, 'which may have been an impetus for Sanofi to do the deal now,' Berens posited. Even so, the analyst still sees Sanofi's bid as a positive for Blueprint and this field of research. Cogent shares were down by about 2% late Monday morning. Recommended Reading Blueprint wins key FDA approval for rare disease drug Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

10 hours ago
Scientists say a record amount of seaweed hit the Caribbean and nearby areas in May
SAN JUAN, Puerto Rico -- A record amount of sargassum piled up across the Caribbean and nearby areas in May, and more is expected this month, according to a new report. The brown prickly algae is suffocating shorelines from Puerto Rico to Guyana and beyond, disrupting tourism, killing wildlife and even releasing toxic gases that forced one school in the French Caribbean island of Martinique to temporarily close. The amount — 38 million metric tons — is the biggest quantity of algae observed across the Caribbean Sea, the western and eastern Atlantic and the Gulf of Mexico since scientists began studying the Great Atlantic Sargassum Belt in 2011, said Brian Barnes, an assistant research professor at the University of South Florida who worked on the report published on Monday by the University of South Florida's Optical Oceanography Lab. The previous record was set in June 2022, with some 22 million metric tons. 'The peaks just seem to keep getting bigger and bigger year after year,' he said. But scientists don't know why yet. 'It's the million-dollar question,' he said. 'I don't have a supremely satisfying answer.' Three different types of sargassum exist in the Caribbean and nearby areas, reproducing asexually as they remain afloat thanks to tiny air sacs. They thrive in different ways depending on sunlight, nutrients and water temperature, factors that scientists are currently studying, Barnes said. Experts also have said that agricultural runoff, warming waters and changes in wind, current and rain could have an effect. While large clumps of algae in the open ocean are what Barnes called a 'healthy, happy ecosystem' for creatures ranging from tiny shrimp to endangered sea turtles, sargassum near or on shore can wreak havoc. It can block sunlight that coral reefs need to survive, and if the algae sinks, it can smother reefs and sea grasses. Once it reaches shore, the creatures living in the algae die or are picked off by birds, Barnes said. Huge piles of stinky seaweed also are a headache for the Caribbean, where tourism often generates big money for small islands. 'It is a challenge, but it's certainly not affecting every single inch of the Caribbean,' said Frank Comito, special adviser to the Caribbean Hotel and Tourism Association. In the popular tourist spot of Punta Cana in the Dominican Republic, officials have invested in barriers to prevent sargassum from reaching the shore, he said. In the Dutch Caribbean territory of St. Maarten, crews with backhoes were dispatched in late May as part of an emergency clean-up after residents complained of strong smells of ammonia and hydrogen sulfide, which can affect a person's respiratory system. 'The smell is quite terrible,' Barnes said. Meanwhile, in the French Caribbean, officials expect to soon use storage barges and an upgraded special vessel that can collect several tons of seaweed a day. The sargassum 'disfigures our coasts, prevents swimming and makes life impossible for local residents,' French Prime Minister François Bayrou recently told reporters. But Comito said such vessels are 'massively expensive' and not a popular option, noting that another option — using heavy equipment —- is labor-intensive. 'You have to be careful because there could be sea turtle eggs affected,' he said. 'It's not like you can go in there and massively rake and scrape the whole thing.' Some Caribbean islands struggle financially, so most of the cleanup is done by hotels, with some offering guests refunds or a free shuttle to unaffected beaches. Every year, the amount of sargassum expands in late spring, peaks around summer and starts to decline in the late fall or early winter, Barnes said. The new record set is hardly stationary — experts said they expect even more sargassum for June.
Yahoo
10 hours ago
- Yahoo
FineHeart Receives ANSM1 Authorization to Deploy Its First-In-Human Clinical Study in France
Patients with advanced heart failure will be treated with FlowMaker®, an innovative, fully implantable device for restoring cardiac output. BORDEAUX, France, June 03, 2025--(BUSINESS WIRE)--FineHeart S.A., a clinical-stage medical technology company specializing in the development of innovative solutions for cardiology, announces that it has received authorization from the French National Agency for the Safety of Medicines and Health Products (ANSM) to initiate its First-In-Human (FIH) clinical trial in France. This prospective, non-randomized study is designed to assess the safety, implant feasibility and preliminary clinical performance of the FlowMaker® device in patients with advanced heart failure. It follows the first successful implantations carried out in 2024 at IKEM (Institute for Clinical and Experimental Medicine) in Prague, whose initial results have been presented at several international scientific congresses. Conducted in several French centers specializing in cardiac surgery, this study represents a decisive step in the clinical development of FlowMaker®. FlowMaker® is a new-generation, fully implantable left ventricular assist device designed to work in synergy with the heart's natural contraction. Less invasive than current devices, this technology aims to preserve native cardiac function while significantly improving patients' quality of life. Pr Pascal Leprince, Head of the Thoracic and Cardiovascular Surgery Department at Hôpital Universitaire Pitié-Salpêtrière (AP-HP) Sorbonne Université and principal investigator of the clinical trial in France, commented: "The launch of this trial in France represents a highly promising step forward for patients with advanced heart failure. Thanks to its pulsatile operation, synchronized with the heart's electrical activity, the FlowMaker® could transform the treatment of these patients, offering them a less invasive and potentially more durable solution than current devices. We look forward to starting this clinical study and confirming these benefits." "ANSM approval marks a key strategic step for FineHeart. It validates the quality and solidity of our preclinical work and confirms the relevance of our initial clinical results. This green light paves the way for the acceleration of our clinical roadmap, with the ambition of responding to a major unmet medical need. It also sends a strong signal to the entire MedTech ecosystem, and to all our partners and investors, whom we thank for their confidence" says Arnaud Mascarell, CEO and co-founder of FineHeart. 1 ANSM: French National Agency for the Safety of Medicines and Health Products About FineHeart - FineHeart View source version on Contacts Europe Media RelationsAnnie-Florence Loyerafloyer@ +33 (6) 88 20 35 59 FineHeart Communications James +33 (0) 7 60 92 77 72